TY - JOUR
T1 - Effective vaccine safety systems in all countries
T2 - A challenge for more equitable access to immunization
AU - Amarasinghe, Ananda
AU - Black, Steve
AU - Bonhoeffer, Jan
AU - Carvalho, Sandra M.Deotti
AU - Dodoo, Alexander
AU - Eskola, Juhani
AU - Larson, Heidi
AU - Shin, Sunheang
AU - Olsson, Sten
AU - Balakrishnan, Madhava Ram
AU - Bellah, Ahmed
AU - Lambach, Philipp
AU - Maure, Christine
AU - Wood, David
AU - Zuber, Patrick
AU - Akanmori, Bartholomew
AU - Bravo, Pamela
AU - Pombo, María
AU - Langar, Houda
AU - Pfeifer, Dina
AU - Guichard, Stéphane
AU - Diorditsa, Sergey
AU - Hossain, Md Shafiqul
AU - Sato, Yoshikuni
PY - 2013/4/18
Y1 - 2013/4/18
N2 - Serious vaccine-associated adverse events are rare. To further minimize their occurrence and to provide adequate care to those affected, careful monitoring of immunization programs and case management is required. Unfounded vaccine safety concerns have the potential of seriously derailing effective immunization activities. To address these issues, vaccine pharmacovigilance systems have been developed in many industrialized countries. As new vaccine products become available to prevent new diseases in various parts of the world, the demand for effective pharmacovigilance systems in low- and middle-income countries (LMIC) is increasing.To help establish such systems in all countries, WHO developed the Global Vaccine Safety Blueprint in 2011. This strategic plan is based on an in-depth analysis of the vaccine safety landscape that involved many stakeholders. This analysis reviewed existing systems and international vaccine safety activities and assessed the financial resources required to operate them. The Blueprint sets three main strategic goals to optimize the safety of vaccines through effective use of pharmacovigilance principles and methods: to ensure minimal vaccine safety capacity in all countries; to provide enhanced capacity for specific circumstances; and to establish a global support network to assist national authorities with capacity building and crisis management.
AB - Serious vaccine-associated adverse events are rare. To further minimize their occurrence and to provide adequate care to those affected, careful monitoring of immunization programs and case management is required. Unfounded vaccine safety concerns have the potential of seriously derailing effective immunization activities. To address these issues, vaccine pharmacovigilance systems have been developed in many industrialized countries. As new vaccine products become available to prevent new diseases in various parts of the world, the demand for effective pharmacovigilance systems in low- and middle-income countries (LMIC) is increasing.To help establish such systems in all countries, WHO developed the Global Vaccine Safety Blueprint in 2011. This strategic plan is based on an in-depth analysis of the vaccine safety landscape that involved many stakeholders. This analysis reviewed existing systems and international vaccine safety activities and assessed the financial resources required to operate them. The Blueprint sets three main strategic goals to optimize the safety of vaccines through effective use of pharmacovigilance principles and methods: to ensure minimal vaccine safety capacity in all countries; to provide enhanced capacity for specific circumstances; and to establish a global support network to assist national authorities with capacity building and crisis management.
KW - Blueprint
KW - Global Vaccine Safety
KW - Global Vaccine Safety Initiative
KW - GVSI
KW - Immunization safety
KW - Post marketing surveillance
KW - Vaccine Safety
UR - http://www.scopus.com/inward/record.url?scp=84876743804&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2012.10.119
DO - 10.1016/j.vaccine.2012.10.119
M3 - Review article
C2 - 23598471
AN - SCOPUS:84876743804
SN - 0264-410X
VL - 31
SP - B108-B114
JO - Vaccine
JF - Vaccine
IS - SUPPL2
ER -